Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients - Tabular View

Tracking Information

First Received Date ^ICMJE

May 23, 2007

Last Updated Date

May 23, 2007

Start Date ^ICMJE

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

diastolic function uric acid levels BNP [ Time Frame: three months ]

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients

Official Title ^ICMJE

Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients

Brief Summary

In patients with chronic heart failure (CHF)due to dilated cardiomyopathy diastolic dysfunction occurs frequently and is related to a poor outcome. We have previously shown that parameters of diastolic function significantly correlate with uric acid levels, a marker of impaired oxidative metabolism. We aimed to determine whether inhibition of xanthine oxidase with allopurinol might affect diastolic function in patients with CHF.

Detailed Description

Study Phase

Phase IV

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Condition ^ICMJE

Chronic Heart Failure

Intervention ^ICMJE

Drug: allopurinol

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

chronic heart failure;
left ventricular systolic dysfunction (ejection fraction <45%)
stable clinical conditions in the previous three months
optimal medical therapy for CHF
normal sinus rhythm
written informed consent
age >18 years

Exclusion Criteria:

renal failure (s-creatinine >2.5 mg/dl)
already on allopurinol
malignancies
chronic inflammatory diseases

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Italy

Administrative Information

NCT ID ^ICMJE

NCT00477789

Responsible Party

Study ID Numbers ^ICMJE

802

Study Sponsor ^ICMJE

Universita di Verona

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Mariantonietta Cicoira, MD, PhD

Division of Cardiology, University of Verona, Italy

Information Provided By

Universita di Verona

Verification Date

May 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP